DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Product Launch
04.06.2018 / 14:00
The issuer is solely responsible for the content of this announcement.
Secarna Pharmaceuticals introduces LNAplusTM, its proprietary, customized, third generation antisense oligonucleotide (ASO) drug discovery and development platform
Munich/Martinsried, Germany, June 4, 2018 – Secarna Pharmaceuticals, a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, announced today the official introduction of the Company’s proprietary, customized, in-house drug discovery platform LNAplusTM at BIO International Convention, taking place June 04-07, 2018 in Boston, USA. Additionally, Secarna has launched their newly redesigned website www.secarna.com, which offers profound information on the LNAplusTM platform as well as a comprehensive understanding of the Company’s drug discovery and development processes.
A powerful platform to generate ASO candidates meeting the highest safety and efficacy requirements
The LNAplusTM platform encompasses all aspects of drug discovery and pre-clinical development, resulting in highly specific, safe and efficacious antisense therapies for challenging or currently not druggable targets. The system’s main components are a proprietary bioinformatics modelling system (OligofyerTM), a best-in-class high throughput screening system, and bespoke target-specific functional assays created by in-house specialists.
“Our state-of-the-art high throughput platform LNAplusTM can be integrated in the process of discovering, testing, and selecting antisense oligonucleotides for pre-clinical and clinical development. It has successfully proven to be fast, reliable, scalable, efficient and provides for a uniquely integrated work flow to deliver best-in-class drug candidates for challenging or previously undruggable targets,” said Jonas Renz, Managing Director and co-founder of Secarna.
Next generation chemical modification: enhancing efficacy and maximising potency
ASOs can control the expression of therapeutically relevant genes by enzyme-dependent degradation of target messenger RNAs (mRNAs). Secarna’s third generation ASOs are characterized by excellent stability and high target affinity. Employing state-of-the-art chemistry, Secarna can achieve an approximately 10-fold increased potency compared to second generation ASOs. Furthermore, Secarna’s ASOs do not require conjugation, transfection and delivery reagents to exert their in vitro and in vivo activity in various cell types, tissues, and organs.
Secarna’s LNAplusTM platform and LNAplusTM based ASOs have been validated by in-house projects as well as in academic and industry collaborations. With over 15 development programs focusing on targets and indications such as immune-oncology, immunology, antiviral, fibrotic diseases, ophthalmology, neurodegenerative diseases and cardiometabolic diseases where antisense-based approaches have clear benefits comparted to other therapeutic modalities, Secarna is a leading antisense drug discovery and development company.
Innovative Antisense Oligonucleotide Therapies
Combining technical capabilities with antisense drug discovery and development expertise, a global KOL network and the Company’s validated partnership model, Secarna is the next generation antisense oligonucleotide company and feels enabled to write new chapters in the book of antisense oligonucleotide discovery and development.
Throughout 2018, Secarna will participate in a number of key scientific and partnering conferences as well as targeted and selected assemblies of the industry.
Meet Secarna at the following conferences taking place in June 2018:
2018 BIO International Convention
3rd Biotech Hanse Forum
If you are interested in meeting the Secarna management team during these events please send an email to email@example.com.
About Antisense Oligonucleotides
Antisense oligonucleotides (ASOs) can control the expression of therapeutically relevant genes. They modulate gene expression by enzyme-dependent degradation of target messenger RNAs (mRNAs). For that, the technology makes use of RNase H1, a cellular enzyme, to cleave the target RNA and consequently silence the expression of encoded proteins. By inhibiting the expression of disease-inducing and -exacerbating proteins, ASOs have the potential to play a critical role as new therapeutics to treat diseases that have been non-treatable or have been treated ineffectively with currently available therapies.
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immunooncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplusTM antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets.
Managing Director and Co-Founder
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
Tel.: +49 (0)89 215 46 375
For media enquiries:
MC Services AG
Tel.: +49 (0)211.52 92 52 22
04.06.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.